Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
| Author | |
|---|---|
| Abstract | :
High-grade serous ovarian carcinoma is characterised by TP53 mutations, DNA repair defects, and genomic instability. We hypothesised that prexasertib (LY2606368), a cell cycle checkpoint kinase 1 and 2 inhibitor, would be active in BRCA wild-type disease. |
| Year of Publication | :
2018
|
| Journal | :
The Lancet. Oncology
|
| Date Published | :
2018
|
| ISSN Number | :
1470-2045
|
| URL | :
http://linkinghub.elsevier.com/retrieve/pii/S1470-2045(18)30009-3
|
| DOI | :
10.1016/S1470-2045(18)30009-3
|
| Short Title | :
Lancet Oncol
|
| Download citation |